Category Archives: Market Access

AMCP Talk Pricing of Specialty Pharma Spurred by Sovaldi

Starting off this week’s Academy of Managed Care Pharmacy (AMCP) meeting in Boston, experts including patient access advocates, pharma and payer representatives came together for this year’s symposium entitled “Specialty Pharmacy and Patient Care: Are We at a Tipping Point?”
Also posted in healthcare, pricing | Tagged , , , , , , , | Leave a comment

Challenges to the Specialty Business Model

By Emily O’Connor, Jillian Scaife, and Ryan P. Million Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Agents such as Gleevec, Zaltrap, and Sovaldi have been under fire from […]
Also posted in Biotech, Strategy | Tagged , , , | Leave a comment

Pharma in Brunei: Growth Potential

Brunei is harnessing its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector, writes Pharmaceutical Technology’s  Jane Wan. Though the Bruneian pharmaceutical sector is in its infancy, it possesses huge potential for growth and development. According to Business Monitor International (BMI), the sector is valued at US$100 million in 2013 […]
Also posted in Global | Tagged , , , , | Leave a comment

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in Biotech, FDA, Guest Blog, healthcare, Legal, Marketing, pricing, Regulatory, Strategy | Tagged , , | 1 Comment

Obamacare's "Unacceptable" Rx Copays

by Tom Norton We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth […]
Also posted in Biotech, Guest Blog, healthcare, leadership, Legal, Strategy | Tagged , , , , , , , | 2 Comments
  • Categories

  • Meta